截至2025年5月23日收盘，阿拉丁(688179)报收于15.23元，下跌0.33%，换手率1.85%，成交量5.14万 手，成交额7837.11万元。 当日关注点 交易信息汇总 5月23日，阿拉丁的资金流向显示，主力资金净流出107.46万元；游资资金净流入266.83万元；散户资金 净流出159.37万元。 公司公告汇总关于实施2024年度权益分派时可转债转股价格调整暨转股连续停牌的提示性公告 上海阿拉丁生化科技股份有限公司计划实施2024年度权益分派，具体方案为每10股派发现金红利1.00元 （含税），并以资本公积每10股转增2股。因实施权益分派，公司可转债将在2025年5月28日至权益分派 股权登记日期间停止转股。公司将于2025年5月29日披露权益分派实施公告和"阿拉转债"转股价格调整 公告。 西部证券股份有限公司作为阿拉丁的保荐人，针对公司募集资金专用账户部分资金被冻结事项进行了核 查。阿拉丁试剂（上海）有限公司在建行上海金桥支行的基本户和中信银行上海闸北支行的募集资金专 户分别被冻结16,553,412.23元和8,935,047.19元，合计25,488,459.42元。冻结原因系上海鼎凯建 ...

以下文章来源于e公司 ，作者证券时报 刘灿邦 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价 的主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 董事长被证监会立案调查，公司2024年年报因资金占用事项被出具非标意见。 5月14日晚间，*ST苏吴（600200）公告，公司收到董事长钱群山通知，其于近日收到中国证监会出具的《立案告知书》（编号：证监立案字0392025008 *ST苏吴表示，本次立案仅针对钱群山个人，不会对公司日常经营活动产生重大影响。立案调查期间，钱群山将积极配合中国证监会的调查工作。 记者注意到，今年2月26日，*ST苏吴收到中国证监会《立案告知书》（证监立案字0392025006号），因公司涉嫌信息披露违法违规，根据《中华人民共和国 证券法》等法律法规，中国证监会决定对公司立案。彼时，*ST苏吴表示，若后续经中国证监会行政处罚认定的事实，触及上交所规定的重大违法强制退市情 形，公司股票将被实施重大违法强制退市。 5月14日晚间披露的另一则公告显示，截 ...

Core Viewpoint - The chairman of *ST Suwu is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact the company's financial reporting and operations in the future [1][2]. Group 1: Investigation and Regulatory Actions - The CSRC has issued a notice of investigation against chairman Qian Qunshan, which is solely directed at him and is not expected to significantly affect the company's daily operations [1]. - The company has received a non-standard opinion on its 2024 annual report due to issues related to the occupation of funds, with a significant amount of 769 million yuan occupied by related parties [4]. - The company will provide weekly updates on the investigation's progress during the ongoing inquiry [2]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, representing a year-on-year decrease of 28.64%, and a net profit attributable to shareholders of 70.48 million yuan [4]. - The company has received an audit report from Zhongxing Caiguanghua Accounting Firm that expresses an inability to provide an opinion on the financial statements due to the aforementioned issues [4]. Group 3: Business Operations and Strategy - *ST Suwu operates in the pharmaceutical sector through its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [2]. - The company aims to develop a dual-driven strategy focusing on both industrial development and capital operations, with plans to enhance its pharmaceutical core while nurturing the medical beauty biotechnology sector as a complementary industry [4]. Group 4: Legal and Financial Challenges - The company’s subsidiary, Jiangsu Wuzhong Import and Export Co., faced legal issues related to export tax fraud, with a court hearing scheduled for April 22, 2025 [5]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [5].